BioNxt Solutions Inc. (FRA:BXT)
0.5860
0.00 (0.00%)
At close: Sep 9, 2025
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 21.66K CAD in the twelve months ending June 30, 2025, down -29.29% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
21.66K CAD
Revenue Growth
-29.29%
P/S Ratio
5,147.24
Revenue / Employee
n/a
Employees
n/a
Market Cap
69.62M EUR
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
Dec 31, 2020 | 345.65K | 137.54K | 66.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Rheinmetall AG | 10.67B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
BioNxt Solutions News
- 18 days ago - Promotional Activity Engagements - Wallstreet:Online
- 21 days ago - BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline - Wallstreet:Online
- 4 weeks ago - BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement - Wallstreet:Online
- 5 weeks ago - BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment - Wallstreet:Online
- 6 weeks ago - BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement - Wallstreet:Online
- 7 weeks ago - BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation - Wallstreet:Online
- 2 months ago - BioNxt Solutions Announces Convertible Debenture Unit Private Placement - Wallstreet:Online
- 2 months ago - BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology - Wallstreet:Online